DEKK-TEC INC

Capabilities

DEKK-TEC was formed in 1983, and has utilized government and private funding to effectively develop new therapies and clinical development candidates for the treatment of cancer, pre-cancerous lesions, and women's health issues. We have previously licensed two of our pipeline products to Biotech/Pharmaceutical companies who have successfully driven these compounds into Phase II clinical development. We also have experience with 510K devise submissions. Our present objective is to continue to create and develop novel drugs and devices for the management of cancer. Our lead therapeutic agents are DM-CHOC-PEN and hydroperoxy analogs.